and trazodone both increase sedation. Use Caution/Monitor.dronedaroneMonitor Closely (1)dronedarone will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.droperidolMonitor Closely (1)droperidol and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and droperidol both increase QTc interval. Avoid or Use Alternate Drug.duloxetineSerious - Use Alternative (1)duloxetine and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.duvelisibMonitor Closely (1)duvelisib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.echothiophate iodideMinor (1)echothiophate iodide increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.efavirenzMonitor Closely (1)efavirenz will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)efavirenz and trazodone both increase QTc interval. Avoid or Use Alternate Drug.elagolixMonitor Closely (1)elagolix decreases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eletriptanMonitor Closely (1)eletriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (1)trazodone, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.eliglustatContraindicated (1)trazodone increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.Serious - Use Alternative (1)eliglustat and trazodone both increase QTc interval. Avoid or Use Alternate Drug.elvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibMonitor Closely (1)encorafenib, trazodone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.Serious - Use Alternative (1)encorafenib and trazodone both increase QTc interval. Avoid or Use Alternate Drug.entrectinibSerious - Use Alternative (1)trazodone and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.enzalutamideMonitor Closely (1)enzalutamide will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ephedrineMonitor Closely (2)trazodone increases effects of ephedrine by unknown mechanism. Use Caution/Monitor. trazodone increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trazodone, ephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.epinephrineMonitor Closely (2)trazodone increases effects of epinephrine by unknown mechanism. Use Caution/Monitor. trazodone increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)epinephrine and trazodone both increase QTc interval. Avoid or Use Alternate Drug. trazodone, epinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.epinephrine racemicMonitor Closely (2)trazodone increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor. trazodone increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)epinephrine racemic and trazodone both increase QTc interval. Avoid or Use Alternate Drug. trazodone, epinephrine racemic. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.ergotamineMonitor Closely (1)trazodone and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.eribulinSerious - Use Alternative (1)eribulin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.erythromycin baseMonitor Closely (1)erythromycin base will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateMonitor Closely (1)erythromycin ethylsuccinate will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateMonitor Closely (1)erythromycin lactobionate will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateMonitor Closely (1)erythromycin stearate will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.escitalopramSerious - Use Alternative (1)escitalopram and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.eslicarbazepine acetateMonitor Closely (1)eslicarbazepine acetate will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.estazolamMonitor Closely (1)estazolam and trazodone both increase sedation. Use Caution/Monitor.estradiolMonitor Closely (1)trazodone will decrease the level or effect of estradiol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Minor (1)estradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens conjugated syntheticMonitor Closely (1)trazodone will decrease the level or effect of estrogens conjugated synthetic by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Minor (1)estrogens conjugated synthetic, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens esterifiedMinor (1)estrogens esterified, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estropipateMonitor Closely (1)trazodone will decrease the level or effect of estropipate by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Minor (1)estropipate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.ethacrynic acidMinor (1)ethacrynic acid, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.ethanolMonitor Closely (1)trazodone and ethanol both increase sedation. Use Caution/Monitor.Minor (1)ethanol, trazodone. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive impairment of motor skills.ethinylestradiolMinor (1)ethinylestradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.ethotoinMinor (1)trazodone increases levels of ethotoin by unspecified interaction mechanism. Minor/Significance Unknown.etodolacMonitor Closely (1)trazodone, etodolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.etomidateMonitor Closely (1)etomidate and trazodone both increase sedation. Use Caution/Monitor.Minor (1)etomidate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.etoposideMonitor Closely (1)trazodone will decrease the level or effect of etoposide by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.etravirineSerious - Use Alternative (1)etravirine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.eucalyptusMinor (1)trazodone and eucalyptus both increase sedation. Minor/Significance Unknown.everolimusMonitor Closely (1)trazodone will decrease the level or effect of everolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fenbufenMonitor Closely (1)trazodone, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fenfluramineMonitor Closely (3)fenfluramine, trazodone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. trazodone and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. trazodone increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trazodone, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.fenoprofenMonitor Closely (1)trazodone, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fesoterodineMinor (1)fesoterodine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.fexinidazoleSerious - Use Alternative (2)fexinidazole and trazodone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval. fexinidazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fexofenadineMinor (1)trazodone will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.finerenoneMonitor Closely (1)trazodone will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.fingolimodSerious - Use Alternative (1)fingolimod and trazodone both increase QTc interval. Avoid or Use Alternate Drug.flavoxateMinor (1)flavoxate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.flecainideMonitor Closely (1)trazodone and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.flibanserinMonitor Closely (1)trazodone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.fluconazoleMonitor Closely (1)fluconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.fludrocortisoneMonitor Closely (2)fludrocortisone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. trazodone will decrease the level or effect of fludrocortisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.fluoxetineMonitor Closely (1)trazodone and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluoxetine and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.fluphenazineMonitor Closely (1)fluphenazine and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)fluphenazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)trazodone, fluphenazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects. trazodone, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.flurazepamMonitor Closely (1)flurazepam and trazodone both increase sedation. Use Caution/Monitor.flurbiprofenMonitor Closely (1)trazodone, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fluvoxamineMonitor Closely (1)fluvoxamine and trazodone both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.formoterolMonitor Closely (1)trazodone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)trazodone and formoterol both increase QTc interval. Avoid or Use Alternate Drug. trazodone, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.fosamprenavirMonitor Closely (1)fosamprenavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fosamprenavir increases levels of trazodone by decreasing metabolism. Avoid or Use Alternate Drug.fosaprepitantMonitor Closely (1)fosaprepitant will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.foscarnetMonitor Closely (1)trazodone and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fosphenytoinMonitor Closely (1)fosphenytoin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Minor (1)trazodone increases levels of fosphenytoin by unspecified interaction mechanism. Minor/Significance Unknown.fostemsavirMonitor Closely (1)trazodone and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.frovatriptanMonitor Closely (1)frovatriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (1)trazodone, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.furosemideMinor (1)furosemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.gabapentinMonitor Closely (1)gabapentin, trazodone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression